HCC

Blue Faery Continues Its Love Your Liver Campaign During Black History Month

Retrieved on: 
Thursday, February 1, 2024

BIRMINGHAM, Ala., Feb. 1, 2024 /PRNewswire/ -- Black/African Americans are 50% more likely to get liver cancer than the general population, and incidence rates are climbing. The Love Your Liver campaign provides community members with convenient opportunities to learn more about their unique liver cancer risks and how to actively manage them. Type 2 diabetes and hepatitis C can both lead to liver cancer, so those in the Black/African American community who currently have or previously had one or both of those diseases are at higher risk for liver cancer. Both type 2 diabetes and hepatitis C are preventable and treatable, so education and early detection are vital to improving survival rates.

Key Points: 
  • Blue Faery is pleased to announce that its annual liver disease and cancer awareness campaign will continue in 2024 during Black History Month.
  • The Love Your Liver campaign provides community members with convenient opportunities to learn more about their unique liver cancer risks and how to actively manage them.
  • Love Your Liver Live, a Black History Month Community Event series, kicks off on February 22, 2024, at 7 p.m.
  • Blue Faery has many educational and advocacy programs, including Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Retrieved on: 
Thursday, January 18, 2024

REDWOOD CITY, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-targeting antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (uHCC). These data are being presented at the 2024 ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 at Moscone West in San Francisco, California. Interleukin (IL)-27 is an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment. Casdozo is a first-in-class antibody, and the only clinical stage immunomodulatory cytokine antagonist targeting IL-27.

Key Points: 
  • These data are being presented at the 2024 ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 at Moscone West in San Francisco, California.
  • Interleukin (IL)-27 is an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment.
  • Casdozo is a first-in-class antibody, and the only clinical stage immunomodulatory cytokine antagonist targeting IL-27.
  • Coherus plans to evaluate the combination of casdozo/toripalimab-tpzi(Coherus’ anti-PD-1 antibody)/bev in future clinical trials.

Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook

Retrieved on: 
Monday, January 29, 2024

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.
  • Fredrik Brag, Chief Executive Officer and Founder of Median Technologies, commented: "In Q4 2023, our iCRO1 business achieved record-high order intake, which increased significantly our backlog.
  • We expect to return to growth in 2024 on the back of a decline in 2023 revenue due to soft order intake in China caused by the Covid lockdowns in 2022 and H1 2023."
  • The Standalone study will be finalized in Q2 2024 and the MRMC study in Q3 2024.

Warrior Met Coal Sets Date for Fourth Quarter 2023 Earnings Announcement and Investor Conference Call

Retrieved on: 
Thursday, January 18, 2024

Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its fourth quarter 2023 investor conference call at 4:30 p.m.

Key Points: 
  • Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its fourth quarter 2023 investor conference call at 4:30 p.m.
  • Warrior Met Coal will release its results following the close of market trading that afternoon.
  • To participate in the conference call, please call 1-844-340-9047 (domestic) or 1-412-858-5206 (international) 10 minutes prior to the start time and reference the Warrior Met Coal conference call.
  • A webcast of the conference call will be available through the Investor section of the Company’s website, http://investors.warriormetcoal.com , where an archived replay will also be available.

Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium

Retrieved on: 
Thursday, January 18, 2024

Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA.

Key Points: 
  • Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA.
  • The poster will highlight the design of the ongoing REVERT LIVER CANCER study, a Phase 1b/2 trial evaluating safety and clinical activity of TTI-101, a novel STAT3 inhibitor, as monotherapy and in combination with standard of care in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).
  • TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3.
  • For more information about the REVERT LIVER CANCER trial, please visit ClinicalTrials.gov (NCT05440708) .

OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook

Retrieved on: 
Friday, January 19, 2024

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.
  • Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “The Company has a broad portfolio of 5 products in clinical development with significant advances reached in 2023 and key milestones expected in 2024.
  • Our shared ambition at OSE is to create value by leading our two advanced assets in phase 2 and phase 3 to a clinical inflection point allowing a structuring agreement.
  • Thus, from Q1 2024, the Company could have validated doses and therapeutic regimens to consider the implementation of possible other clinical trials.

Medivir invites to a conference call today on updated data at ASCO GI and the plans moving forward for fostrox in primary liver cancer (HCC)

Retrieved on: 
Tuesday, January 23, 2024

The data was presented at the ASCO (American Society of Clinical Oncology) GI (Gastrointestinal Cancers) Symposium in San Francisco on January 19.

Key Points: 
  • The data was presented at the ASCO (American Society of Clinical Oncology) GI (Gastrointestinal Cancers) Symposium in San Francisco on January 19.
  • The conference call will be held today January 23, at 14.00 CET, to update on the results in the study and the plans moving forward, including feedback from extensive interactions with world renowned experts at the ASCO GI congress.
  • -  "The updated study results presented at ASCO GI has further strengthened our belief in the combination of fostrox + Lenvima as a potential treatment for patients with advanced HCC.
  • The conference also enabled extensive interactions with global experts in HCC which provided important input regarding the design of our upcoming study.

Laredo Oil, Inc. Announces Agreement to Drill Up to Three Wells in Montana

Retrieved on: 
Monday, January 22, 2024

The Participation Agreement will initially provide $2,034,000 million in cash to fund the drilling of a development well and the acquisition of certain leases currently held by Lustre Oil Company, LLC, a wholly owned subsidiary of the Company, in the Midfork Field in Montana.

Key Points: 
  • The Participation Agreement will initially provide $2,034,000 million in cash to fund the drilling of a development well and the acquisition of certain leases currently held by Lustre Oil Company, LLC, a wholly owned subsidiary of the Company, in the Midfork Field in Montana.
  • Several of the participating investors also hold $575,000 in the Company's convertible debt, plus accrued interest, which investments are included as investments under the Participation Agreement.
  • After the repayment to the investors, the split between the investors and HCC and Erehwon will be on a 50%/50% basis.
  • After the development well is drilled, the investors have the option to invest in up to two additional wells in the field.

Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium

Retrieved on: 
Wednesday, January 17, 2024

-     "We are excited by these results in a poor prognosis patient population where low disease control and response rates are usually seen.

Key Points: 
  • -     "We are excited by these results in a poor prognosis patient population where low disease control and response rates are usually seen.
  • The updated data presented at ASCO GI has further strengthened our belief in the combination of fostrox + Lenvima as a potential treatment for patients with advanced HCC.
  • These data show that fostrox + Lenvima have encouraging results related to clinical outcome in patients with second-line advanced HCC without jeopardizing safety.
  • The poster will be available on Medivir's website after it has been presented at ASCO GI.

Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024

Retrieved on: 
Tuesday, January 16, 2024

TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.

Key Points: 
  • TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.
  • First, the company will share findings in hepatocellular carcinoma (HCC) and cholangiocarcinoma during the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI24), which is taking place from January 18-20.
  • Tasurgratinib, for which a marketing authorization application was submitted in Japan in December 2023, is an orally available selective tyrosine kinase inhibitor of FGFR1-3.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancers.